{"id":"W2087779901","doi":"10.1007/s10637-014-0091-8","title":"A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Bicalutamide; Medicine; Vandetanib; Prostate cancer; Tolerability; Internal medicine; Urology; Oncology; Adverse effect; Pharmacology; Cancer; Tyrosine kinase; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004546302,0.0002168143,0.0006118939,0.0002572756,0.0000820765,0.00001957441,0.00005971346,0.00005640123,0.00002638707],"category_scores_gemma":[0.0001606398,0.0001436294,0.00002620096,0.0005518118,0.0003672706,0.0001559255,0.00002142934,0.0001933356,6.782323e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002190949,"about_ca_system_score_gemma":0.0005558571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00127423,"about_ca_topic_score_gemma":0.000863933,"domain_scores_codex":[0.9979584,0.0001947349,0.0005163637,0.0003653564,0.000729152,0.0002359592],"domain_scores_gemma":[0.9987887,0.0004239396,0.0001945977,0.0001627146,0.0002281947,0.0002019226],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8316548,0.005960167,0.1412515,0.0001061998,0.000415116,0.00001992864,0.009518619,0.0005324469,0.001158283,0.0004718667,0.00003470247,0.008876382],"study_design_scores_gemma":[0.6671062,0.004854322,0.325499,0.0003089039,0.00008931223,6.417138e-7,0.0002069577,0.0008108549,0.000670328,0.0002910669,0.00002778061,0.0001347082],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939567,0.0001026942,0.00001640178,0.002347194,0.0000283546,0.003424918,0.00002074976,0.00001779586,0.00008511919],"genre_scores_gemma":[0.9987682,0.00005069157,0.0005030014,0.000103838,0.00002637343,0.0001885385,0.0001685312,0.00002502804,0.0001657743],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1842474,"threshold_uncertainty_score":0.5857038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01768645514526797,"score_gpt":0.3041144943748178,"score_spread":0.2864280392295498,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}